ライフサイエンスコーパス: reteplase

1 those receiving combination of abciximab and reteplase.

2 ase and abciximab versus those randomized to reteplase.

3 lity at 30 days compared with a full dose of reteplase.

4 nment (streptokinase, 4.1%; alteplase, 4.3%; reteplase, 4.5%; combined streptokinase and alteplase, 4

5 tients receiving abciximab with reduced-dose reteplase (5 U double bolus) showed an 86% incidence of

6 ed with reduced doses of either alteplase or reteplase, abciximab achieved 91% and 83% inhibition of

7 taly, and Poland were treated with half-dose reteplase, abciximab, heparin, and aspirin, and randomly

8 d, open-label trial to compare the effect of reteplase alone with reteplase plus abciximab in patient

9 reinfarctions with the combination than with reteplase alone, and there was less need for urgent reva

10 year compared with fibrinolytic therapy with reteplase alone.

11 ed, compared with 468 (5.6%) in the combined reteplase and abciximab group (odds ratio 0.95 [95% CI 0

12 assess whether the combination of half-dose reteplase and abciximab provides any propitious benefits

13 e randomized to the combination of half-dose reteplase and abciximab versus those randomized to retep

14 Although combined reteplase and abciximab was not superior to standard ret

15 t a non-interventional centre with half-dose reteplase and abciximab.

16 The effects of reteplase and alteplase on platelet aggregation and majo

17 ht to compare platelet characteristics after reteplase and alteplase therapy in the setting of the Gl

18 the first 24 h of coronary thrombolysis with reteplase and alteplase.

19 tandard-dose reteplase (n=8260) or half-dose reteplase and full-dose abciximab (n=8328).

20 Tenecteplase and reteplase are comparable with accelerated infusion recom

21 Aggregation was higher after reteplase at 24 h when induced by 5 micromol/liter adeno

22 arly treatment with abciximab plus half-dose reteplase (combination-facilitated PCI) or with abcixima

23 2.4%, p = 0.62) among patients randomized to reteplase compared to those receiving combination of abc

24 Combination therapy (abciximab and reteplase) did not reduce mortality over 1 year compared

25 and a half dose of a plasminogen activator (reteplase) did not significantly reduce mortality at 30

26 t 7 days occurred in 3.5% of patients in the reteplase group and 2.3% of patients in the combination

27 urred in 692 (8.38%) of 8260 patients in the reteplase group and 698 (8.38%) of the 8328 patients in

28 At 30 days, 488 (5.9%) of patients in the reteplase group had died, compared with 468 (5.6%) in th

29 The truncated t-PA variant reteplase had a minor effect on permeability, whereas ur

30 However, after reteplase, indicators of platelet activity were higher a

31 cs, pharmacodynamics, plasminogen activator, reteplase, lanoteplase, and tenecteplase.

32 arction were randomly assigned standard-dose reteplase (n=8260) or half-dose reteplase and full-dose

33 d after reperfusion with either alteplase or reteplase or reduced doses of these agents with concomit

34 o compare the effect of reteplase alone with reteplase plus abciximab in patients with acute myocardi

35 Neither facilitation of PCI with reteplase plus abciximab nor facilitation with abciximab

36 oprotein inhibitors; RR 1.88 [1.24-2.86] for reteplase plus parenteral anticoagulants plus glycoprote

37 One such activator, reteplase (r-PA), was compared with t-PA in the Global U

38 ospital initiation of the bolus fibrinolytic reteplase (rPA) and determined the time saved by prehosp

39 se (accelerated infusion), tenecteplase, and reteplase should be considered over streptokinase and no

40 e and abciximab was not superior to standard reteplase, the 0.3% absolute (5% relative) decrease in 3

41 Reteplase therapy exhibited greater glycoprotein (GP) II

42 to 24 h after thrombolysis, especially after reteplase therapy.

43 o receive (intravenously) a standard dose of reteplase (two 10-U boluses, 30 minutes apart) or the co

44 icro g/min for 12 hours]) and a half dose of reteplase (two 5-U boluses, 30 minutes apart).

45 a combination of abciximab and reduced-dose reteplase was safe and effective.

46 Thirty-two patients receiving reteplase were randomly assigned infusions of either ins

47 (streptokinase, tenecteplase, alteplase, and reteplase) were included.

48 ted infusion of alteplase, tenecteplase, and reteplase with parenteral anticoagulants as background t